Suppr超能文献

成人玻璃体视网膜疾病中白内障超声乳化吸除联合人工晶状体植入术与微创玻璃体切除术的临床疗效

Clinical Outcomes of Combined Phacoemulsification With Intraocular Lens Placement and Microincision Vitrectomy in Adult Vitreoretinal Disease.

作者信息

Muns Sofía M, Villegas Victor M, Murray Timothy G, Latiff Azeema, Gold Aaron S

机构信息

Department of Ophthalmology, University of Puerto Rico, San Juan, PR, USA.

Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.

出版信息

J Vitreoretin Dis. 2022 Nov 14;7(1):27-32. doi: 10.1177/24741264221118185. eCollection 2023 Jan-Feb.

Abstract

PURPOSE

To evaluate the safety and clinical outcomes of combined phacoemulsification with intraocular lens (IOL) placement and microincision vitrectomy surgery (MIVS) in adult patients with concomitant cataract and vitreoretinal disease.

METHODS

A consecutive series of patients with comorbid vitreoretinal disease and cataract who had combined phacoemulsification with IOL placement and MIVS was retrospectively analyzed. The main outcome measures were visual acuity (VA) and intraoperative and postoperative complications.

RESULTS

The analysis comprised 648 eyes of 611 patients. The median follow-up was 26.9 months (range, 12-60 months). The most common vitreoretinal pathology was intraocular tumor (53%). The best-corrected Snellen VA improved from 20/192 at baseline to 20/46 at the 12-month follow-up. The most frequent intraoperative complication was capsule tear (3.9%). The most common postoperative adverse events after 3 months of follow-up (mean, 24 months) were vitreous hemorrhage (3.2%) and retinal detachment (1.8%). No patient developed endophthalmitis.

CONCLUSIONS

Combined phacoemulsification with IOL placement and MIVS is a safe, effective technique to manage a broad range of vitreoretinal diseases in patients with significant cataract.

摘要

目的

评估成年合并白内障和玻璃体视网膜疾病患者行白内障超声乳化吸除联合人工晶状体(IOL)植入术与微创玻璃体切除术(MIVS)的安全性及临床疗效。

方法

回顾性分析一系列连续的合并玻璃体视网膜疾病和白内障且接受白内障超声乳化吸除联合IOL植入术与MIVS的患者。主要观察指标为视力(VA)以及术中、术后并发症。

结果

分析纳入611例患者的648只眼。中位随访时间为26.9个月(范围12 - 60个月)。最常见的玻璃体视网膜病变为眼内肿瘤(53%)。最佳矫正视力从基线时的20/192提高到随访12个月时的20/46。最常见的术中并发症为晶状体囊膜撕裂(3.9%)。随访3个月(平均24个月)后最常见的术后不良事件为玻璃体积血(3.2%)和视网膜脱离(1.8%)。无患者发生眼内炎。

结论

白内障超声乳化吸除联合IOL植入术与MIVS是治疗伴有明显白内障的多种玻璃体视网膜疾病的一种安全、有效的技术。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验